All In Biotech

Drug Trial Radar · NCT07802730

Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

Comparison of Pharmacokinetics of Glycopyrrolate (AERO-002) in AERO-007 Combination Product Versus Active Comparator Inhalation Glycopyrrolate Product in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 21, 2026

Primary completion

Oct 9, 2026

Study completion Oct 9, 2026

Sponsor

Lead sponsor
AeroRx Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Medicines Evaluation Unit Ltd
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, single-dose, 2-period crossover study in healthy volunteers to compare the systemic pharmacokinetic (PK) profile of inhaled AERO-002 versus inhaled active comparator product.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • AERO-002 (60 mcg)Drug

    Single dose, administered via inhalation using a standard jet nebulizer

  • Glycopyrrolate (18 mcg)Drug

    Single dose, administered via inhalation using pMDI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - AUCTime frame: 0 to 24 hours post-dose
  2. Pharmacokinetics - CmaxTime frame: 0 to 24 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicines Evaluation Unit Ltd

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.